Digital Health,
Journal Year:
2024,
Volume and Issue:
10
Published: Jan. 1, 2024
Myriad
digital
health
interventions,
applications,
devices
and
technologies
have,
are,
being
developed
to
help
refine
personalise
medicine
from
the
patient,
healthcare
professional
(HCP),
system
industry
perspectives.
At
a
gathering
of
leaders
in
health,
discussion
included
current
landscape
such
tools
(DHTs),
with
specific
examples
cardiology
respiratory
medicine,
both
benefits
sometime
downfalls
tools.
While
DHTs
can
patients
HCPs
detect
monitor
conditions,
experts
discussed
how
adoption
may
be
hampered
by
issues
as
access
technology;
data
privacy
security
concerns;
technology
integration
into
systems;
cost
reimbursement;
lack
guidelines
regulatory
hurdles.
The
suggested
solutions
issues,
including
wider
availability
‘booths’
local
patient;
easy
understand
use
phone
applications;
patient
HCP
incentives
clear
paths
within
system.
These
should
aid
shared
decision-making
and,
ultimately,
streamline
for
all.
Allergy,
Journal Year:
2023,
Volume and Issue:
78(10), P. 2790 - 2794
Published: Aug. 11, 2023
The
concept
of
'one-airway-one-disease',
based
on
the
links
between
upper
and
lower
airway
allergic
diseases,1
may
be
an
oversimplification.
ARIA-MeDALL
(Allergic
Rhinitis
its
Impact
Asthma-Mechanisms
Development
ALLergy)
hypothesis—based
genomic,
epidemiologic
clinical
findings—proposed
that
rhinitis
alone
(R)
a
distinct
entity
from
asthma
multimorbidity
(A
+
R),
with
therapeutic
relevance.2
However,
hypothesis
has
not
been
tested
using
real-world
data.
aim
this
study
was
therefore
to
assess
differences
in
symptoms
medications
R
A
data
MASK-air®,
freely
available
mHealth
app.
methods
are
fully
described
online
supplement.
Briefly,
previous
study,
k-means
cluster
analysis,
we
identified
three
groups
MASK-air®
users:
those
having
'probable
asthma',
'possible
asthma'
or
'no
evidence
(R).4
In
assessed
(2015–2020)
cross-sectionally
compared
patients
(i)
their
maximum
median
reported
visual
analogue
scale
(VAS)
values
for
global
allergy
symptoms,
nasal,
ocular
as
well
impact
work,3
(ii)
combined
symptom-medication
score
(allergy-CSMS5)
(iii)
medication
component
allergy-CSMS.
We
performed
sensitivity
analysis
sample
physician-diagnosed
current
asthma,
past
no
asthma.
Finally,
longitudinally
users
frequency
complete
weeks
displaying
well-controlled,
partly-controlled,
variably-controlled
uncontrolled
rhinitis.
analysed
3797
25
countries
(256,839
days)
(Table
S1
online,
Figure
online).
total
1733
provided
(14,409
weeks).
Patients
displayed
meaningfully
higher
VAS
allergy-CSMS
than
1).
were
moderate–high
eye,
work
There
meaningful
when
treatments
groups:
more
asthma'.
Robust
results
obtained
subanalysis
282
enrolled
by
physicians
(Tables
S2
S3
levels
each
country
>100
2).
For
levels,
moderate
large
observed
all
comparing
versus
Small
found
most
percentage
controlled
ranged
62.8%
('possible
asthma')
80.0%
('no
asthma'),
while
partly-controlled
12.6%
27.9%
S4
app,
that,
comparison
R,
display
nasal
increased
use
CSMS
individually
different
countries,
suggesting
generalisability
finding.
Although
some
associated
high
effect
sizes
there
have
user-/day-related
selection
biases
information
(e.g.
classification),
these
overall
support
existence
control
considering
R.
Overall,
although
excluding
other
hypotheses,
is
line
hypothesis.
Clinically,
supports
assessment
possibility
severe
supported
EU
grants
(POLLAR,
EIT
Health;
Structural
Funds,
Twinning,
EIP
AHA,
H2020
Horizon
Europe)
educational
Mylan-Viatris,
ALK,
GSK,
Novartis
Uriach.
JB
responsible
design,
manuscript
writing
(original
draft).
BSP
RJV
remaining
authors
collection
critical
revision
editing
manuscript.
None.
reports
personal
fees
Cipla,
Menarini,
Mylan,
Novartis,
Purina,
Sanofi-Aventis,
Teva,
Uriach,
KYomed-Innov,
MASK-air-SAS,
outside
submitted
work.
owns
shares
SAS
KYomed-Innov.
VK
Norameda,
BerlinCHemie
DLL
Allakos,
Amstrong,
Astrazeneca
national
global,
Chiesi,
DBV
Technologies,
Grunenthal,
GSK
Mylan/Viatris,
MSD,
Pfizer,
Sanofi,
Siegfried,
UCB,
Carnot,
Abbvie,
Lilly,
Astrazeneca,
Circassia,
Purina
institute,
FR
nonfinancial
AstraZeneca,
Medinfar,
Azentis,
SPAIC,
LTB
LETI,
Vitoria
Laboratories,
TZ
Henkel,
Bayer,
FAES,
Astra
Zeneca,
AbbVie,
Almirall,
Astellas,
Bencard,
Berlin
Chemie,
Hal,
Leti,
Mesa,
Merck,
Stallergenes,
Takeda,
Kryolan,
L'Oreal,
work;
Organizational
affiliations:
Commitee
member:
WHO-Initiative
'Allergic
Its
Asthma'
(ARIA);
Member
Board:
German
Society
Allergy
Clinical
Immunology
(DGAKI);
Head:
European
Centre
Research
Foundation
(ECARF);
President:
Global
Asthma
Network
(GA2LEN);
Member:
Committee
Diagnosis
Molecular
Allergology,
World
Organization
(WAO).
COI
disclose,
Wienczyslawa
Czarlewski,
Anna
Bedbrook,
Tari
Haahtela,
Ludger
Klimek,
Oliver
Pfaar,
Piotr
Kuna,
Maciej
Kupczyk,
Boleslaw
Samolinski,
Arunas
Valiulis,
Rute
Almeida,
Cristina
Jácome,
Arzu
Yorgancioglu,
Karl-Christian
Bergmann,
Sinthia
Bosnic-Anticevich,
G
Walter
Canonica,
Victoria
Cardona,
Lorenzo
Cecchi,
Claudia
Chaves
Loureiro,
Alvaro
Cruz,
Bilun
Gemicioglu,
Wytske
J
Fokkens,
Juan
Carlos
Ivancevich,
Helga
Kraxner,
Daniel
Laune,
Renaud
Louis,
Michael
Makris,
Mario
Morais-Almeida,
Joaquim
Mullol,
Marek
Niedoszytko,
Yoshitaka
Okamoto,
Nikolaos
Papadopoulos,
Vincenzo
Patella,
Nhân
Pham-Thi,
Philip
W
Rouadi,
Joaquin
Sastre,
Nicola
Scichilone,
Aziz
Sheikh,
Mikhail
Sofiev,
Sanna
Toppila-Salmi,
Ioanna
Tsiligianni,
Erkka
Valovirta,
Mihaela
Zidarn,
Rita
Amaral,
Ignacio
Ansotegui,
Louis-Philippe
Boulet,
Guy
Brusselle,
Roland
Buhl,
Denis
Charpin,
Philippe
Devillier,
Virginie
Doyen,
Ewa
Jassem,
Joos,
Jutel,
Thomas
Keil,
Kulus,
Olga
Lourenço,
Ralph
Mösges,
Rachel
Nadif,
Stefania
Nicola,
Alberto
Papi,
Jean-Louis
Pépin,
Benoit
Pétré,
Francesca
Puggioni,
Santiago
Quirce,
Sietze
Reitsma,
Nicolas
Roche,
Monica
Rodriguez-Gonzalez,
Ana
Sá-Sousa,
Marine
Savouré,
Faradiba
S
Serpa,
Milan
Sova,
Annette
Sperl,
y,
Omar
Usmani,
Peter
Valentin
Tomazic,
Olivier
Vandenplas
Data
sharing
applicable
article
new
created
analyzed
study.
Appendix
S1.
Please
note:
publisher
content
functionality
any
supporting
supplied
authors.
Any
queries
(other
missing
content)
should
directed
corresponding
author
article.
Clinical Interventions in Aging,
Journal Year:
2024,
Volume and Issue:
Volume 19, P. 971 - 979
Published: May 1, 2024
Purpose:
To
analyse
factors
affecting
the
ability
to
use
digital
asthma
monitoring
application
Mask-Air
®
in
old-age
individuals
living
inland
Portugal.
Patients
and
Methods:
In
this
observational
study,
patients
with
medically
confirmed
who
agreed
participate
were
interviewed
subdivided
into
Non-users
Group:
those
could
not
Users
could.
Sociodemographic
psychological
data,
comorbidities,
status
compared
between
groups.
Assessment
of
reasons
for
refusal
was
based
on
a
6-item
questionnaire.
Results:
Among
72
sequentially
recruited
(mean
age
±
SD
73.26±
5.43
yrs;
61
women;
11
men),
44
(61.1%;
mean
age±SD
74.64±
5.68
38
6
men))
included
Group
28
(38.9%;
71.11±
4.26
23
5
men)
Group.
significantly
older,
had
lower
socioeconomic
level,
more
frequently
severe
(25%
vs
3.6%;
Odds
ratio=0.08
(95%
CI=0.01–
0.81;
p=0.033))
diabetes
(32.6%
7.4%;
ratio=0.17
CI=0.03–
0.80;
p=0.025))
than
The
main
using
App
"Lack
required
hardware"
(n=35)
"Digital
illiteracy"
(n=26),
but
lack
interest
among
conditions
it
uncommon.
Conclusion:
Most
asthmatics
Beira
Interior
either
smartphone
or
skills,
which
are
significant
obstacles
implementing
app-based
studies.
Plain
Language
Summary:
This
study
done
see
whether
possible
mobile
phone
(App)
help
inner
Central
Portugal
better
monitor
self-manage
their
disease.
researchers
group
proven
study.
two
subgroups:
(44
patients)
because
they
did
have
smartphone;
(28
all
App.
helped
download
(called
MASK-Air),
given
thorough
explanation
about
it,
how
should
be
used
daily
basis
symptoms.
found
that
worse
conditions,
often
diabetes.
They
also
discovered
knowing
smartphone.
These
results
show
lacking
tools
frequent
situations
Portugal,
these
may
own
Keywords:
asthma,
mHealth,
literacy,
disease
monitoring,
Clinical and Translational Allergy,
Journal Year:
2024,
Volume and Issue:
14(6)
Published: May 28, 2024
Abstract
Rationale
It
is
unclear
how
each
individual
asthma
symptom
associated
with
diagnosis
or
control.
Objectives
To
assess
the
performance
of
symptoms
in
identification
patients
and
their
association
Methods
In
this
cross‐sectional
study,
we
assessed
real‐world
data
using
MASK‐air
®
app.
We
compared
frequency
occurrence
five
(dyspnea,
wheezing,
chest
tightness,
fatigue
night
symptoms,
as
by
Control
Allergic
Rhinitis
Asthma
Test
[CARAT]
questionnaire)
probable,
possible
no
current
asthma.
calculated
sensitivity,
specificity
predictive
values
symptom,
between
control
(measured
e‐DASTHMA
score).
Results
were
validated
a
sample
physician‐established
Measurement
Main
included
951
(2153
CARAT
assessments),
468
having
probable
asthma,
166
317
evidence
Wheezing
displayed
highest
(90.5%)
positive
value
(90.8%).
dyspnea
tightness
more
strongly
than
other
symptoms.
Dyspnea
was
sensitivity
(76.1%)
one
consistently
e‐DASTHMA.
Consistent
results
observed
when
assessing
physician‐made
Conclusions
for
diagnosis,
while
strongest
Digital Health,
Journal Year:
2024,
Volume and Issue:
10
Published: Jan. 1, 2024
Myriad
digital
health
interventions,
applications,
devices
and
technologies
have,
are,
being
developed
to
help
refine
personalise
medicine
from
the
patient,
healthcare
professional
(HCP),
system
industry
perspectives.
At
a
gathering
of
leaders
in
health,
discussion
included
current
landscape
such
tools
(DHTs),
with
specific
examples
cardiology
respiratory
medicine,
both
benefits
sometime
downfalls
tools.
While
DHTs
can
patients
HCPs
detect
monitor
conditions,
experts
discussed
how
adoption
may
be
hampered
by
issues
as
access
technology;
data
privacy
security
concerns;
technology
integration
into
systems;
cost
reimbursement;
lack
guidelines
regulatory
hurdles.
The
suggested
solutions
issues,
including
wider
availability
‘booths’
local
patient;
easy
understand
use
phone
applications;
patient
HCP
incentives
clear
paths
within
system.
These
should
aid
shared
decision-making
and,
ultimately,
streamline
for
all.
